AbbVie gets final EU approval for Allergan acquisition

3 March 2020
abbvie_sign_large

As part of US biopharma major AbbVie’s (NYSE: ABBV) $6.3 billion acquisition of Ireland-incorporated Allergan (NYSE: AGN) announced last year, the European Commission has approved the divestiture of brazikumab, an investigational interleukin (IL)-23 inhibitor in development for autoimmune diseases, to AstraZeneca (LSE: AZN).

The candidate was licensed to Allergan by the Anglo-Swedish pharma major in 2016,  under a potential $1.27 billion deal.

The European Commission's approval of AbbVie's pending acquisition of Allergan in January was conditional upon the divestiture of brazikumab to a suitable purchaser. The transaction remains subject to additional customary closing conditions, but the European Commission's final approval clears the pathway in Europe to close the pending transaction.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology